After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cancer and autoimmune disorders, for which conventional ...

Trump threatens extra tariffs on countries siding with Brics, escalating trade tensions ahead of August deadline.

In his latest move to reset global trade terms, the US president has formally notified Japan and South Korea that 25% tariffs are heading their way, effective 1 August. He claims their trading ...